Mirum Pharmaceuticals 3Q 2026: Revenue $185.72M, Net income ($40.77M), EPS ($0.87) — 10-Q Summary

What happened

Mirum Pharmaceuticals reported third-quarter 2026 product sales of $185.72M, up 39.6% from a year earlier. It recorded a net loss of $40.77M, versus net income of $2.91M, and diluted earnings per share, meaning profit or loss allocated to each share after accounting for potential extra shares, were a loss of $0.87 compared with $0.05 income.

Confirmed

Global impact / market context

Sales growth, led by Livmarli and Bile Acid Medicines, shows rising product revenue, but the shift from profit to a substantial loss points to costs or other items outweighing that growth. Investors will need later results to see whether sales gains translate into improved profitability and cash available.

Analyst inference

The article also reports progress in clinical testing and plans for a Livmarli regulatory application, but these are future developments rather than current sales. Their eventual outcomes could affect the company’s ability to expand revenue, while trial and application timelines leave uncertainty alongside the reported loss.

Analyst inference

What to watch

1. Compare upcoming product sales with the reported $185.72M level, especially Livmarli and Bile Acid Medicines, to assess whether growth continues across Mirum’s medicines. Analyst inference
2. Watch for the planned Livmarli supplemental application in the first half of 2027; approval would require regulatory review and could enable broader use if granted. Proposed
3. Look for AZURE-4 results expected in the fourth quarter of 2026 and volixibat PBC data expected in the first quarter of 2027, as reported. Confirmed

Evidence

• Original source link unavailable